Business Context and Reporting Period
Filing identity: The supplied filing is Eliem Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2022 (filed August 15, 2022), not a filing for Climb Bio, Inc. This is a material mismatch with the request metadata.
Eliem is a clinical-stage biotechnology company developing therapies for neuronal excitability disorders. It had no approved products and generated no product revenue. Its lead candidate was ETX-155; the company subsequently discontinued ETX-810 development.
Financial Results and Position
Amounts below are in millions of dollars, except per-share data. The company reported no revenue; profit and operating margins are therefore not meaningful.
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Research and development, including related-party expense | $8.8 | $5.8 | $17.0 | $10.5 |
| General and administrative expense | $4.9 | $2.9 | $9.8 | $5.1 |
| Total operating expenses | $13.7 | $8.7 | $26.8 | $15.6 |
| Net loss | $14.6 | $8.7 | $27.8 | $27.3 |
| Net loss per share, basic and diluted | $0.56 | $3.11 | $1.06 | $8.80 |
| Operating cash used | Not separately stated | Not separately stated | $24.7 | $15.2 |
At June 30, 2022, cash and cash equivalents were $32.6 million, short- and long-term marketable securities totaled $102.1 million, and combined cash and securities were $134.7 million, down from $161.4 million at December 31, 2021. Total liabilities were $7.9 million, including $0.7 million of operating lease liabilities; the filing reports no borrowings or debt. Accumulated deficit was $103.4 million. Unrealized investment losses recorded in other comprehensive loss were $0.5 million for the first six months.
Material Changes, Outlook, and Risks
- Q2 operating expenses rose 57% year over year; six-month operating expenses rose 72%. Management attributed the increase mainly to clinical-trial costs, higher headcount and stock-based compensation, public-company costs, and insurance.
- Six-month operating cash use increased to $24.7 million from $15.2 million. Management’s operating plan estimated available cash and securities would fund operations into 2025, while the financial-statement liquidity note stated they were sufficient for at least 12 months from the filing date. These are estimates dependent on assumptions; additional funding will be needed to advance and commercialize programs.
- ETX-155’s Phase 2a depression program was delayed after lower-than-expected drug exposure in a Phase 1b photosensitive epilepsy study. A Phase 1 pharmacokinetic study began in July 2022; results were expected in Q4 2022. If exposure and safety were confirmed, the company expected to start an MDD Phase 2a trial in Q1 2023, with topline data anticipated in mid-2024. The planned PMD trial was postponed; the PSE trial might be reconsidered after the pharmacokinetic results.
- On August 2, 2022, the company reported that ETX-810 failed to achieve statistical separation from placebo on the primary endpoint in its LSRP Phase 2a trial. Following an earlier DPNP Phase 2a failure, it discontinued ETX-810 development.
- Management expected expenses and operating losses to increase. Risks include clinical and manufacturing setbacks, dependence on third parties, the need for further financing, foreign-exchange exposure, and possible COVID-19-related delays. The filing reported no material legal proceedings and no off-balance-sheet arrangements.
- Disclosure controls were deemed ineffective at June 30, 2022 because of material weaknesses in accounting staffing and procedures, segregation of duties, and IT general controls. Remediation was underway; management said the weaknesses had not caused a financial-statement misstatement but could affect timely detection of one.
Investor Verification Priorities
- Confirm the issuer: the filing identifies Eliem Therapeutics, Inc., while the request names Climb Bio, Inc.
- Reconcile reported share counts: the balance-sheet text states 26,567,681 shares at June 30, while the equity rollforward shows 26,327,401; 26,567,681 is also reported as outstanding on August 11, 2022.
- Track ETX-155 pharmacokinetic, CMC, exposure, and safety findings against the stated development milestones and timelines.
- Assess the impact of ETX-810’s discontinuation on the pipeline, spending plan, and projected cash runway.
- Monitor cash burn, financing needs, and progress in remediating the disclosed internal-control material weaknesses.